<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82791">
  <stage>Registered</stage>
  <submitdate>30/04/2008</submitdate>
  <approvaldate>15/05/2008</approvaldate>
  <actrnumber>ACTRN12608000248369</actrnumber>
  <trial_identification>
    <studytitle>The role of Gabapentin in the treatment of refractory chronic dry cough.</studytitle>
    <scientifictitle>The role of Gabapentin in the treatment of refractory chronic dry cough: A randomised double-blind placebo-controlled study.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>chronic cough</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>300 mg of oral Neurontin once per day, then increased to 600mg/d for second day, then 900mg/d for third day upto maximum tolerable dose of 1800mg/day for ten weeks.</interventions>
    <comparator>placebo-lactose (sugar pill)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Improvement in cough quality of life by Leicester Cough Questionnaire (LCQ)</outcome>
      <timepoint>baseline, during treatment visit (week 8) end of treatment visit (week 12) and post treatment visit (week 16).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Decrease in cough reflex senstivity</outcome>
      <timepoint>baseline, during treatment visit (week 8), end of treatment visit (week 12) and post treatment visit (week 16).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Decrease in cough frequency by cough monitor recording</outcome>
      <timepoint>baseline, during treatment visit (week 8), end of treatment visit (week 12) and post treatment visit (week 16).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in cough severity by Cough visual analogue scale (vas)</outcome>
      <timepoint>baseline, during treatment visit (week 8), end of treatment visit (week 12) and post treatment visit (week 16).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Persistent non-productive cough of more than 8 weeks duration,
Male or female between ages of 18 and 80 years,
Non-smoker or ex-smoker with less than 10 pack years,
To have been well during the 4 weeks prior to study entry,
Informed consent obtained.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Productive cough,
Current smoker,
Smoking history &gt;10 pack years,
Pregnancy/breast feeding,
Other respiratory disease, eg: bronchiectasis, COPD.
Inability to attend study visits
Respiratory tract infection during month prior to randomisation
Impaired liver function at Visit 1 as shown by Aspartate aminotransferase (AST), an enzyme normally present in liver and heart cells and alanine aminotransferase (ALT). If the liver is injured, the liver cells spill the enzymes into blood, raising the enzyme levels in the blood and signaling liver damage.
Therefore, an AST, ALT, alkaline phosphatase or total bilirubin greater than 2 times the upper limit of normal will exclude a participant.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>allocation concealment-central randomisation by computer to pharmacy for active or placebo allocation to subject whois along with the investigators blinded to allocation.</concealment>
    <sequence>Permuted block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2 />
    <masking3>True</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>7/05/2008</anticipatedstartdate>
    <actualstartdate>15/10/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/09/2010</actualenddate>
    <samplesize>56</samplesize>
    <actualsamplesize>62</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Hunter New England Area Health Service</primarysponsorname>
    <primarysponsoraddress>Lookout Road,
New Lambton Heights NSW 2305.</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC CCRE PhD Scholarship</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601 </fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC Project Grant</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601 </fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Surinder S Birring</othercollaboratorname>
      <othercollaboratoraddress>Department of Respiratory Medicine,

King's College Hospital,

Denmark Hill,

London,

SE5 9RS </othercollaboratoraddress>
      <othercollaboratorcountry>United Kingdom</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>looking at effectiveness of treating persistent cough with a medication</summary>
    <trialwebsite />
    <publication>Trial related presentations/publications

Presentations: 
1) Recent additions in the treatment of cough. Invited Keynote Speaker, 1st International Cough Conference, Guangzhou China, November 2013.
2) Gabapentin Treatment for Refractory Chronic Cough: a Randomized Controlled Trial. Clinical science poster Invited Oral Abstract, Seventh International Symposium on Cough Taming Chronic Cough. Imperial College London, UK, July 2012.
3) CICADA Cough Symposium: Gabapentin for idiopathic chronic cough: A randomised controlled trial Invited Speaker, Thoracic Society of Australia and New Zealand (TSANZ), Canberra, Australia, April 2012.
4) Review: 3rd American Cough Conference Invited Oral, VIVA Presentation, HMRI, July 2011.
5) Gabapentin for Idiopathic Chronic Cough: A randomised controlled trial, Oral, 3rd American Cough Conference, June 2011.

Publications:
1) Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough-Author's reply. The Lancet. 2013; 381(9867): 624-5.
2) Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012; 380: 1583-89.
</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Research Ethics Unit</ethicname>
      <ethicaddress>Hunter Area Headquarters
Lookout Road,
New lambton NSW 2305.</ethicaddress>
      <ethicapprovaldate>6/05/2008</ethicapprovaldate>
      <hrec>08/03/19/3.04</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Peter G Gibson</name>
      <address>Level 2 West Wing, HMRI
Lot 1 Kookaburra Circuit
New Lambton Heights NSW 2305.</address>
      <phone>+612 40420142</phone>
      <fax>+612 40420046</fax>
      <email>Peter.Gibson@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Nicole M Ryan</name>
      <address>Clinical Toxicology Research Group, Level 5 New Med Building
Calvary Mater Newcastle, Waratah NSW 2298.</address>
      <phone>+61249211312</phone>
      <fax>+61240143873</fax>
      <email>Nicole.Ryan@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Nicole M Ryan</name>
      <address>Clinical Toxicology Research Group, Level 5 New Med Building
Calvary Mater Newcastle, Waratah NSW 2298.</address>
      <phone>+61249211312</phone>
      <fax>+61240143873</fax>
      <email>Nicole.Ryan@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Peter G Gibson</name>
      <address>Level 2 West Wing, HMRI
Lot 1, Kookaburra Circuit
New Lambton Heights NSW 2305.</address>
      <phone>+61240420142</phone>
      <fax>+61240420046</fax>
      <email>Peter.Gibson@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>